1

Brown and Warren keep their promise: no third party ads

 

By Will Holt

On August 20,  the Boston Globe published a front-page story by staff writer Noah Bierman titled “Brown, Warren pledge holds up.” In January, Bierman writes, Senator Scott Brown and Professor Elizabeth Warren agreed to keep third-party ads out of the Massachusetts Senate race despite their recent inundation of airwaves elsewhere across the country.

This agreement between the Republican incumbent and his Democratic challenger comes only two years after the decision in the now-infamous Citizens United case, in which the United States Supreme Court effectively ruled — to put it rather bluntly — that money is speech and corporations are people in the realm of campaign finance law. Whatever one thinks of either Warren or Brown, they’re certainly bucking a national trend.

With an eye toward the rest of the country in this heated election season, Bierman writes that over $90 million have been in spend in 13 states with Senate races this year alone. None of this money, trickling down from political action committees (PACs) and other interest groups, has so much as paid for a sound bite in the election here in Massachusetts.

You have to wonder how the candidates are making this work in what might very well be one of the country’s most acrimonious, grudging, and competitive Senate race this year. But early on they came up with a relatively simple solution: every time a third-party group runs an advertisement, the party that benefits from the advertisement’s message must make a donation to charity directly out of its own coffers.

The Brown-Warren pledge represents a model for the rest of the country, one that should be strictly adhered to in an election season that promises to be rife with a slew of misinformation and even outright lies. And while I’ll refrain from coming down in this post for one candidate or the other, I should mention that I have a great deal of respect for both Scott Brown and Elizabeth Warren in light of this agreement. At least the candidates are speaking for themselves.

–Will Holt also blogs at Letters from a Bay Stater, where this blog initially appeared.  http://williambrianholt.wordpress.com/

 

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning  marketing and communications firm.




Fareed Zakaria: Will US maintain its innovation lead in new global landscape?

CNN host Fareed Zakaria said yesterday that despite the world’s current economic and political difficulties,   he is optimistic about the future  but that it is by no means clear “who will be winners and the losers”  in what he called a “new global landscape.”

In a keynote talk at the Biotechnology Industry Organization International Convention in Boston,  Zakaria said, that the world is currently “extraordinarily  peaceful” compared with previous decade and that it is quite “unified, with a global economic system, interactive communications and technology and greater computing power than ever before.  (For example,  the cell phone has more computing power than did the Apollo spacecraft capsule in 1969. ” It could go to the moon, he said, but it could not tweet,”  he quipped. )

In the past, he said, the US has always been able to emerge from  economic difficulties  due to its tremendous capacity to innovate–and in the second half of the twentieth century, maintained a substantial economic and innovative edge over other nations.  But, he said, “we forget that at other times, other countries have  had the edge.”    He asked, “Will the US  maintain its edge?”

Zakaria outlined what he called three distinct historical  phases or causes that, he said, account for the US’  “extraordinary” lead:

(1) During World War II, the forces of destruction had a huge spillover effect.  Germany, a major US competitor, was “leveled to the ground” and England was bankrupted.

(2) During the Cold War, fears of losing out to the USSR in the 1950s  led the US government to make double the investment in US companies than it is making now;  government purchases of US computers and components accounted for the lion’s share of profits for those companies, until the cost curve began to decline. What is more, the government invested heavily in higher education, so that citizens could obtain the world’s finest education in public universities” without paying a cent”

(3) “The third pillar was Jews ” he said. “If  Hitler had not made the morally reprehensible to target Jews, the US would not have had the influx of scientists who created the bomb, transformed theoretical physics and gave the US a 30-year lead.”

What this shows, he said,  is that America’s propensity of innovate is “not due to DNA,” but rather, that there are specific historical reasons why the US took a commanding lead.

Today, he said, there is a new global landscape  in which it is possible for smaller nations– such as Denmark, where  the Global company Novo Nordisk, known for its diabetes treatments,  was founded–  to be at the leading edge in certain technologies.

What is more, Zakaria pointed out,  innovation does not necessarily correlate directly with spending for research and development.  Apple is often considered one of the most innovative companies in the world–but that is because it understood consumers and  how to create a new need,  rather than because it offers the most cutting edge technology, he said.  “Big company and big country advantages no longer hold, going forward.”

On a panel following the talk, Kiran Mazumdar-Shaw, founder and chair  of the Indian biotechnology company Biocon, said that the current process of biotechnology development is unsustainable and most products are too expensive to benefit most of those who need them.  “Countries in Asia must reinvent the process of drug innovation,” she said.

Greg Lucier, CEO of Life Technologies, which supplies systems, biological reagents and services to enable scientific research, said that  new genomics tools will be the stimulus to streamline innovation, cut costs,  and change the future of  human health.

Derek Hanekom,  South Africa’s Deputy Minister of Science and Technology emphasized the importance of  government’s role in providing access to care and sanitation. Governments can promote innovation by recognizing and supporting it,  reducing unnecessary regulations yet adding regulations to promote competition, and supporting  education to develop a skilled workforce.

Yucel Altunbasak, president of Tubitak, the Scientific and Technological Research Council of Turkey, listed financing, talented people, regulatory framework, and a governmental support mechanism as keys to helping emerging markets do “what the US did in the 1950’s.”

 

 

 

 

 




Companies Receive $1.3 M in MA-Israeli Collaboration Grants

Four Massachusetts-Israeli business collaborations have received a total of $1.3M in grant funding under the  Massachusetts-Israel Innovation Partnership (MIIP)–a  formal collaboration between the State of Israel and the Commonwealth of Massachusetts to encourage and support innovation and entrepreneurship between Massachusetts’ and Israel’s life sciences, clean energy and technology sectors.

The grants were announced yesterday at the  2012 BIO International Convention in Boston by Massachusetts  Governor Deval Patrick and  Israeli Chief Scientist Avi Hasson, of  MATIMOP, the  Israel Ministry of Industry, Trade and Labor.

The four winning projects are:

  • SBH Sciences (Natick) and Improdia (Israel) will work together toward the development and manufacture of a chronic inflammation-dependent immunosuppression prognostic kit. SBH will receive $184,000 from the Center and Improdia will receive $202,000 from Israel’s OCS.SBH Sciences is a discovery and preclinical contract research organization with expertise in production and analysis of cytokines and biomarkers. Improdia is a life science start-up focused on implementing novel biomarkers for immune system modulating therapies– using  simple blood tests for patients with chronic disease.
  •  Automated Medical Instruments (AMI – Needham) and STI Lasers (Israel) will develop new technology involving radio frequency energy to perform circumferential ablation of the pulmonary veins. AMI will receive $116,000 from the Center and STI Lasers will receive $110,000 from OCS. AMI is a start-up medical device company developing novel technology to perform atrial fibrillation treatment. STI Lasers is a medical device company specializing in laser cutting, micromachining and finishing of miniature metal components.“AMI is developing the CircumBlator™,  to offer a reliable and curative, minimally invasive treatment for millions of patients with atrial fibrillation, a disease that causes over 20 percent of strokes and untold misery,” said Martin Sklar, President and CEO of Automated Medical Instruments.
  • Lantheus Medical Imaging, Inc. (North Billerica) and Check-Cap (Israel) will  develop a novel 3-D imaging capsule that can be used to screen for polyps and lesions associated with colorectal cancer. Lantheus will receive $300,000 from MTC and Check-Cap has been selected to receive at least an equal amount from OCS. Lantheus  develops, manufactures and distributes innovative diagnostic imaging agents. Check Cap is a medical device company located in Mount Carmel, Israel with a “breakthrough” solution for Colorectal Cancer Screening.  “As a global leader in diagnostic imaging, Lantheus is dedicated to providing physicians with breakthrough new tools to enhance patient care. Teaming up with Check-Cap to develop and manufacture a cutting-edge imaging capsule further advances this ongoing commitment,” said Don Kiepert, President and CEO, Lantheus Medical Imaging.
  • FloDesign Sonics (Wilbraham) and Transbiodiesel (Israel)  will use FloDesign’s acoustic molecule separation technology to separate oil that can be used to create fuel from Transbiodiesel’s oil-generating algae. FloDesign Sonics will receive $55,000 from MassCEC and Transbiodiesel will receive $20,958 from OCS. FloDesign Sonics uses a novel ultrasonic acoustophoretic separation technology developed at Western New England University for a more efficient approach to wastewater treatment and micro-algae harvesting for biofuels. Transbiodiesel is a start- up company with a novel technology for producing biodiesel fuels from a variety of oils

The MIIP program was first announced in June 2011 at the BIO International Convention in Washington, D.C. and the first joint solicitation for proposals was launched in September 2011 by MATIMOP on the Israeli side and by the three participating Massachusetts agencies: the Massachusetts Life Sciences Center, the Massachusetts Technology Collaborative (MTC) and the Massachusetts Clean Energy Center (MassCEC). Total funding for the current projects is approximately $3m.

The partnership came as a result of a 2011 trade mission in which  Governor Patrick and a coalition of Massachusetts business executives and senior government officials explored growth opportunities of common interest for Massachusetts’ and Israel’s innovation industries. During that mission Governor Patrick and Shalom Simhon, Israeli Minister of Industry, Trade and Labor, signing on behalf of their respective states, signed a Memorandum of Understanding (MOU) in Jerusalem. MIIP was established to implement the MOU’s framework.

Massachusetts is the first U.S. state to establish a significant industrial R&D program with the State of Israel, according to a press release issued yesterday by Patrick’s office.

Today there are nearly 100 companies with Israeli founders or Israeli-licensed technologies in Massachusetts, according to the release.  In 2009, these companies employed nearly 6,000 people and generated $2.4 billion in direct revenue for the state. Local firms exported over $180 million worth of goods to Israel in 2009. Home to 377 hospitals and 37,000 practicing physicians, Israel is an important market for health-related technologies.

The New England-Israel Business Council, the US-Israel Science and Technology Foundation, the Government of Israel Economic Mission to North America, the Consulate General of Israel to New England and MOITI have all played an important role in promoting the program, according to the release.

–Anita M. Harris

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning strategic public relations,  marketing communications and thought leadership firm in Cambridge, MA.

 




AC Immune/Genentech to Partner on R&D for Alzheimer’s Antibody; $418M Agree’t

PRESS RELEASE

· New antibody program targets Tau protein, a major cause of Alzheimer’s disease

· License agreement potentially worth more than Swiss Francs 400 Million (approximately USD 418 million*)

Lausanne, Switzerland, 18 June, 2012 – AC Immune SA, today announced that it has entered into a second exclusive worldwide license agreement and research collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for the research, development and commercialization of AC Immune’s anti-Tau antibodies for the potential treatment of Alzheimer’s disease and other neurodegenerative diseases.

Under the terms of the agreement, AC Immune will receive an undisclosed upfront payment and is eligible to receive research, development and commercialization milestone payments totaling more than Swiss Francs 400 million (approximately USD 418 million*) for Alzheimer´s disease and other indications. Additionally, AC Immune is eligible to receive royalties on net sales of products resulting from the collaboration. Under the multi-year joint research collaboration, AC Immune will work in partnership with Genentech to identify and formulate several pre-clinical candidates. Genentech will have global responsibility for pre-clinical and clinical development, manufacturing and commercialization of antibodies resulting from the collaboration.

Prof. Andrea Pfeifer, CEO of AC Immune said: “We are delighted to continue our excellent relationship with Genentech through this second landmark deal to fight Alzheimer’s disease. This underlines Genentech’s trust in AC Immune’s proprietary technology platform and we are confident in our joint abilities to develop not only
first-in-class but also best-in-class medication for one of the biggest healthcare problems of this century.”

“This second licensing deal gives us financial security to continue AC Immune’s
world-leading efforts to develop disease modifying therapies and diagnostics. We are now recognized as having one of the broadest and most advanced Alzheimer’s pipelines in the industry”, remarked Martin Velasco, Chairman of The Board of AC Immune .

Commenting on the deal, James Sabry, Genentech’s Vice President of Partnering , said: “Genentech is committed to bringing innovative treatments to patients suffering from devastating neurodegenerative diseases, and is developing a number of approaches to tackle Alzheimer’s disease. The addition of this anti-Tau program to our CNS pipeline complements other approaches we are investigating, including crenezumab which we in-licensed from AC Immune in 2006.”

About the anti-Tau Program

The Tau protein forms twisted fibers inside brain cells and build tangles that are considered by many in the scientific community as the second major cause of Alzheimer’s disease besides Abeta-plaques. The anti-Tau antibodies were discovered and humanized by AC Immune through its proprietary SupraAntigen TM technology.

“The anti-tau-antibodies have proven highly specific to misfolded Tau in relevant animal models for Alzheimer’s disease and are therefore well suited to be developed as a disease-modifying drug. This has significant potential as there are at present no known cures for Alzheimer’s disease,” said Dr. Andreas Muhs, Chief Scientific Officer
of AC Immune .

About Crenezumab

An anti-Abeta antibody, crenezumab was discovered and humanized by AC Immune. It is designed to bind to amyloid beta (Abeta), the main constituent of amyloid plaque in the brains of patients with Alzheimer’s disease. Abeta is considered to be a major cause in the development of the disease. Genentech is currently evaluating crenezumab in a Phase II clinical study in Alzheimer’s patients with mild to moderate symptoms. At the time the deal with Genentech was announced in December 2006, it was stated to have a potential total value of more than USD 300 million in clinical and regulatory milestone payments to AC Immune, excluding royalties.

In May 2012, crenezumab was selected to be tested in the world’s first-ever prevention trial in healthy individuals who are genetically destined to develop Alzheimer’s disease. This landmark study to investigate whether an anti-amyloid treatment can stave off the disease is being run by the US National Institutes of Health (NIH), the Banner Alzheimer’s Institute (BAI), the University of Antioquia in Colombia and Genentech.

About Alzheimer’s Disease

Alzheimer´s is the most common form of dementia. It is degenerative, irreversible and terminal. The memory and thinki ng of the patients is progressively destroyed. Besides the personal aspect there is a huge social and economic impact. Alzheimer´s disease is recognized as a significant health crisis of the 21st century with currently more than
36 million patients worldwide. This number is expected to double in the next 20 years and to triple to more than 116 million by 2050. In 2010 global worldwide costs were estimated to be USD 604 billion and were exceeding 1% of the global domestic product (Reference: World Alzheimer Report 2011, Alzheimer’s Disease International).

Scientists don’t yet fully understand what causes Alzheimer’s disease, but it has become increasingly clear that it develops because of a complex series of events that take place in the brain over a long period of time. Two proteins – Tau and Abeta – are perceived as the major causes of neurodegeneration: tangles and other abnormal forms of Tau protein accumulate inside the brain cells, while plaques and oligomers formed by Abeta occur outside the brain cells of people with Alzheimer’s disease.

About AC Immune SA
AC Immune SA is a Swiss-based biopharmaceutical company and a leader in Alzheimer´s disease drug development. AC Immune develops innovative therapeutics with “best in class” potential against Alzheimer´s disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. The anti-Abeta antibody (crenezumab) for passive immunization is partnered with Genentech and is in Phase II development. The company continues to develop in house the small molecule ACI-91 and the vaccine ACI-24 in Phase II and Phase I/IIa clinical development respectively. These three clinical programs are focused on Alzheimer’s disease, and are backed by a rich portfolio of preclinical compounds. The therapeutic molecules are also leveraged for Alzheimer´s disease diagnostic and other central nervous system and non-CNS diseases, such as Glaucoma. Since its foundation in 2003, AC Immune has raised CHF 64 million from private investors.

 

-Anita M. Harris
Disclosure: I will be working with AC Immune at the Biotechnology Industry Organization today in Boston.

 

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning strategic public relations,  marketing communications and thought leadership firm in Cambridge, MA.




Newsrooms Must Adopt “Innovation Culture” To Survive, Google Exec says

Richard GingrasNewspapers have long kept tabs on the changing world–but have themselves been slow to modernize. To  flourish these days,
when anyone with a computer can be a publisher,  news organizations must develop a “culture of innovation. ”

So said Richard Gingras, the head of News Products at Google,  on May 11, 2012 in a talk at Harvard’s Nieman Foundation.

Gingras, a founder of Salon.com and long-term media technologist , said “I push people to rethink every aspect of what they’re doing”–including their mission, ethical guidelines, how they interact with their audiences, transparency regarding sources,  and even whether reporters divulge their personal political positions. In light of today’s powerful new technologies and human interactions,  “innovation  must be part of an organization’s DNA,”  at the core of newspapers’ culture, and  incorporated into “the role of every member of the team.”

Gingras pointed out that this by no means the first “disruption” time for the media.  With the advent of television,  for example, newspaper advertising declined and in some cities, the number of newspapers went from five to one or two.   This was not great for the newspapers that went out of business and  led to monopolitistic control by the  survivors. But it also led to    “40  golden years of profitability” for those survivors.

Today, the Internet has “disaggregated” the advertising economy., he said.  No longer do consumers look to their local newspapers for car ads, for example: rather, they search the Internet for information and deals.  “In the past, you could have an ad in the New York Times for Tiffany’s near an article on starvation in Darfur… or articles for garden centers in  the Lifestyles section,” Gingras said.   But on the Internet, such “vertical models” for advertising  are not effective.  ” Might news organizations’ Web sites do better as “a stable of focused brands with independent business models?” he asked.

Gingras also suggested that news organizations:

  • Optimize news Web sites for multiple entry points,  because individual story pages are, today, more valuable than first or home pages. These individual pages should be updated so that urls remain constant–thus optimizing search engine results.
  • Include more “computational journalism”–in which reporters post interactive information tables that would allow readers to answer their own, individualized questions.  For example, in a story on the state of education, provide tables showing student progress in school districts across the city–so that parents could assess statistics on their own children’s schools
  •  Leverage the assistance of  “the trusted crowd”  (interact with readers and keep them involved)
  •  Make reporters responsible for updating their own stories–with “constant” urls  to encourage multiple visits to their pages

Gingras also said that  in a culture of bulletpoints, updates and posts,  there  is low return on investment for long articles–and advised keeping articles  under 500 words.

So  I’ll quit here–at 494.

A video of the complete talk  is posted at: http://www.nieman.harvard.edu/newsitem.aspx?id=100198

–Anita M. Harris

Anita Harris, a former national journalist and Nieman Fellow,  is president of the Harris Communications Group, a marketing and communications firm located in Cambridge, MA.




Downturn + changing VC industry = funding challenges for startups

For entrepreneurs seeking venture capital funding, there’s good news—and there’s bad news. The good news is that  it’s easier now than at any time in the last ten years to get relatively small amounts of seed money. The bad news is that it’s harder to obtain “A Round” or additional series funding after that.

That was the consensus of  three Boston area venture capitalists who spoke at the Cambridge Innovation Center on  Wednesday, May 2.  Moderator Ben Hron of  law firm McCarter -English, which sponsored the event, asked the VCs  how the 2008 economic downturn  has impacted the VC industry;  where things stand now,  and what they foresee for the future.

Impact of the recession
A changing industry
Jo Tango, founder and partner of Kepha Partners, which invests in early stage companies, said that for many VC firms, this is a period of innovation. “We call it VC 2.0,”  he quipped to the audience of  entrepreneurs.  The VC industry, which started in about 1980, used to be dominated by approximately 20 major firms; today, there are more smaller, more specialized VC firms, he said.

David Beisel, co-founder and partner of  NextView Ventures, a dedicated seed-stage venture capital firm focused on Internet startups, said that the downturn has “facilitated a  maturation process,” which he likened to what happened in the beer industry in the 1990s.

That is, “You had to be either one of the biggest, like Anheuser-Busch—or a microbrewery.” Mid-size companies like Genesee fell by the wayside.

Likewise,  today,  he said, “VC firms are no longer trying to be all things to all entrepreneurs; they’re taking a dedicated approach.  Recently, four or five firms raised more than $1B but mid-sized firms are struggling.”

CA Webb, Executive Director of the New England Venture Capital Association, said that considering this a time of “introspection and innovation” is “optimistic…The reality is that the industry is taking a hard look at itself. Some say that the ‘sky is falling,’ because there’s less money being invested; this means that some firms will shut down. Those that succeed will need to articulate clearly just what they are willing to offer and to whom.”

Tango pointed out that “Innovation [in the VC industry] creates a challenge for entrepreneurs because VC firms are “all over the map,” and “it’s difficult to know which one is right for [a particular startup]. It’s easier now to get seed money–but terms are often more difficult to distinguish.”

 

Current trends
In asking the panelists for their views on the current venture funding situation, Hron shared Q1 2012 statistics showing  a large number of deals but a drop in total funding compared with previous quarters– in indicating fewer “megadeals.”  “Should entrepreneurs should be optimistic because of the number of deals or pessimistic about the size of the deals?” he asked.

Fewer large deals
Tango responded that one reason for the decline in large deals has to do with the number of deals VCs have previously closed.  In the current economic climate, he explained, it’s difficult raise a stream of money. In a recent study of five VC Web sites, his firm found that many VCs are already sitting on the boards of 10-17 companies in which they have invested. “If you’re fundraising…if you’re already on 15 boards, you need to spend your time fund raising,” not sitting on additional boards.

Smaller investments
Beisel described what he called a longer term trend:  in some sectors, especially digital media, companies don’t need to raise as much money for initial funding as in other sectors–so at earlier stages, the venture community is reacting by not writing $5M checks but rather $1M or .5 M.

In Webb’s view, “seeding is now like the old Series A funding: there is a lot of seed money to go around but Series A is now looking like the old series C “(IE–difficult to come by).

Follow-on funding can be problematic.
Tango agreed –describing a firm that backed 20 companies with seed money but told him it will provide only 2 % of those with Series A funding.  He added that the situation is even more complicated because even at the “seed stage,”different VCs require different terms.

In fact, he recommended, “Ninety per cent of startups should be bootstrapped (funded by self, friends and family) because other investors expect that they will get their money out within a few years. “With VC funding, you’re becoming a fiduciary…taking on ‘credit card debt’ that you will need to pay back.”

In Beisel’s view, before taking any money from VCs, an entrepreneur needs to know how outsiders view the firm, the reputation of the VC firm, which partner will be best for the company, and whether the firm usually adds to series funding or “will you be one of the 98% that get dropped?”

Health care vs. other  investment
Citing a decline in financing for health care ventures in Massachusetts compared with increased financing for Internet and mobile technology, Hron asked if investors are seeking short-term gains as instead of  taking the long view required for biotechnology and pharma payback.

Webb responded that one reason for the slowdown in health care company funding is that the US Food and Drug Administration is taking longer to approve products so the horizons for investors are longer. As a result, investors are shifting toward healthcare technology, “big data” and products that will bring a quicker return.

In Beisel’s view, “Over the last ten years the returns for health care investment have not been that great; health care is now even more challenging. But VCs won’t shift to other spaces; the money just won’t get raised.”

Long -term trends
According to Hron, the data suggest a rise in VC investing in Washington State, Texas, and Illinois. “Are we seeing the rise of a national VC community or is this a blip?” he asked. “And will VC investors look at companies nationwide?”

Tango and Beisel agreed that large investors are looking at companies nationally and internationally–especially in the Internet space.

They also agreed that it’s unlikely that VCs will spring up in Kansas or in “third-tier American cities,” as Beisel; put it.  In Tango’s view, “they will still be centered in Boston, NY and California.”  Beisel pointed out that that VC firms are on the rise in nations like Argentina and Eastern Europe.  According to Webb, “Capital clusters around academic institutions: You won’t see much density elsewhere.”

Crowd sourcing
Regarding the  recent passage of legislation allowing corporate fundraising through crowd sourcing, panelists expressed concerns about possibilities for fraud and entry of organized crime; and also  that unsophisticated investors might not know that seasoned professionals expect to lose money on most  investments—in hopes that a few will have big payoffs.

Asked by Hron if VCs will look askance at companies raising initial funding through crowd sourcing, Beisel said  that it’s fine to get seed money wherever you can but a “real company” will need institutional investors in order to grow large.

In Tango’s view, “Your source of funding depends on what you want to accomplish: Do you just want to get money…or are you looking for series of VC rounds, advice and support?”

 

PANELIST BIOs

David Beisel – David is Co-Founder and Partner of NextView Ventures, a dedicated seed-stage venture capital firm focused on investments in internet startups.  Previously he was an investor at both Venrock and Masthead Venture Partners, where he served on the boards of BlogHer and Gazelle.  Prior to joining Masthead, he co-founded Sombasa Media, an e-mail marketing company which was successfully acquired by About.com and subsequently became a division of Primedia (NYSE: PRM), where he served as Vice President of Marketing.  He is also the founder of the Web Innovators Group, a quarterly entrepreneur-focused event which attracts nearly a thousand attendees.  David blogs atwww.GenuineVC.com.

Jo Tango – Jo is Founder and Partner of Kepha Partners, an early-stage venture capital firm.   Previously, Jo spent was a General Partner at Highland Capital Partners, where he worked for nearly nine year, and before that he spent five years with Bain & Company.  Jo has invested in the e-commerce, search engine, Internet ad network, wireless, supply chain software, storage, database, security, on-line payments and data center virtualization spaces.  He has been a founding or first institutional investor in Azuki Systems, Bit9, ExaGrid, StreamBase Systems, Vertica Systems (acquired by Hewlett-Packard), Virtual Iron (acquired by Oracle) and VoltDB, getting involved nearly always at the company inception phase. Other investments include Ask Jeeves (Nasdaq: ASKJ), Digital Market (acquired by Agile Software), and NextCard (Nasdaq: NXCD).

C.A. Webb – C.A. became the Executive Director of the New England Venture Capital Association in January 2012.  Members of the NEVCA include more than 700 venture capital professionals from over 100 firms that collectively manage more than $50 billion in capital.  C.A. has spent her career in entrepreneurial roles with mission driven, early stage and high growth organizations. Her work has focused on breakthrough business models in a diverse array of industries including retail and packaged goods (Whole Foods Market), consumer internet technology (Care.com), sustainability (Preserve Products), historic preservation (Trinity Boston Foundation), public education (Boston Collegiate Charter School), and publishing (Fast Company magazine




Cambridge Local Unions Protest With Huge Inflated Rat

Rat balloon-insulators, tin knockers, pipefitters union protest  Local AFL-CIO Insulators, Tin Kinockers and Pipefitters from Cambridge Local  use a large inflatable rat to make clear how they feel about the use of non-union, non-Cambridge workers by PH Mechanical for work currently underway at 302 Third Street in Kendall Square.  “They don’t conform to community standards; they are unlicensed, and they have no apprentice program,” said one union member who declined to give his name. He said he expects that Cambridge City Council will be discussing the issue at its next meeting, possibly this evening.

 Photos C. Anita M. HarrisInsulators, Tin Knocker, & Pipefitters Local AFL-CIO unions protest use of non-union workers at 302 3rd St.

—Anita M. Harris

Anita Harris is a writer in Cambridge, MA.  New Cambridge Observer is a publication of the Harris Communications Group,  a marketing and public relations firm based in Kendall Square, Cambridge.




Filmmaker uses novel site to fundraise for doc on Boston 60s WBCN rock politics radio

My friend Bill Lichtenstein is working on what’s certain to be a wonderful nonprofit documentary film about WBCN–a groundbreaking Boston radio station deeply involved in the political and cultural changes of the 1960s.  He’s seeking funding through Kickstarter: an innovative fundraising mechanism that will be of interest to entrepreneurs of all stripes–in order to help change the future.

The film, entitled  “The American Revolution: How a Radio Station, Politics and Rock and Roll Changed Everything”  documents Boston radio station WBCN from 1968 (when Bill, as a 14-year-old high school became the station’s youngest DJ) through 1974.

As reported in the Boston Herald (Dec. 5, 2011), during those years, Bruce Springsteen did his first radio interview ever on WBCN;  Jerry Garcia and Bob Weir,  of the Grateful Dead, and  the Allman Brothers’ Duane Allman stopped into the studio at 2 AM and jammed for an area. When Nixon invaded Cambodia, “BCN got local college kids to strike.

WBCN  “had tremendous national impact both musically and politically,” Lichtenstein told the Herald. “We changed the world one time,” Lichtenstein says.  And, with this film,  “we can do it again.”

Lichenstein, who has produced TV news and documentaries for ABC and PBS, has gathered more than 50,000 documents, photos,  and tapes–which include performances by Led Zeppelin, Lou Reed and the Velvet Underground.

He has also garnered some $50,000 in contributions–but needs to double that amount by Dec. 19 to complete the film.

He’s  seeking $104 thousand in donations via Kickstarter–a nonprofit that allows contributors tax deductions–but gives fundraisers just a month to get the entire bundle.That is, Kickstarter takes an all or nothing approach:  Lichtenstein must  bring in all $104K by Dec. 19–or he gets nothing.

After three weeks of fundraising, he’s  now almost at the halfway point, with just a week to go.

More info and the film trailer are available at  www.KickstartWBCN.com.  Lichtenstein and Kickstarter will be featured on Boston’s WCVB-TV  “Chronicle”  on Dec. 13, 2011.

——Anita Harris

Anita M. Harris is president of the Harris Communications Group, an award-winning public relations firm located in tyhe Cambridge Innovation Center in Kendall Square,  Cambridge, MA.   Anita  is a former national journalist who got HER start in the alternative press–as a founder of the Harrisburg Independent Press and writer for  the The Real Paper and Phoenix in Boston, MA.